Agenus Inc

AGENNASDAQ · USD
5.97USD0.00 (-2.77%)
5210

Agenus Inc (AGEN) Implied Volatility Current

AGEN's 30 day implied volatility is 90.25%, with an IV Rank of 4.76%. This is a low IV Rank versus the past year, meaning Agenus Inc options are relatively cheap and currently favor buyers. AGEN's 30 day historical volatility sits at 77.15%, which means implied volatility is running 13.10 points above historical volatility, as of Nov 19, 2026.

Read more

Tracking AGEN implied volatility helps you spot when Agenus Inc options are historically cheap or expensive, and where the best trades are hiding. When AGEN IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor AGEN implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking AGEN IV rank helps you see whether AGEN's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody.

Implied Volatility

IV Rank
4.76%IV Rank
Low

IV is subdued. Premiums are cheap, favoring buyers.

Implied Volatility (30d)90.25%

IV Rank4.76%

Historical Volatility (30d)77.15%

IV Minus HV+13.10%

As of Nov 19, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →